ARTICLE | Company News
Primagen, bioMerieux CoV-NL63 deal
February 2, 2006 3:49 AM UTC
Primagen (Amsterdam, The Netherlands) granted bioMerieux (Euronext:BIM) exclusive rights to the CoV-NL63 coronavirus to develop a diagnostic test. Primagen is eligible for undisclosed milestones and r...